RAMM Pharma Corp.
RAMM
CNSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -8.23% | -15.08% | -13.61% | -2.75% | 6.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.23% | -15.08% | -13.61% | -2.75% | 6.74% |
| Cost of Revenue | -40.86% | -45.06% | -1.25% | 13.97% | 20.50% |
| Gross Profit | 448.04% | 308.34% | -54.64% | -69.73% | -58.87% |
| SG&A Expenses | 45.31% | 42.46% | -17.75% | -13.96% | -19.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -18.12% | -16.96% | -- | 6,853.33% | 7,428.57% |
| Total Operating Expenses | 11.70% | 8.33% | -11.60% | -4.17% | -6.74% |
| Operating Income | -25.44% | -25.09% | 10.24% | 5.07% | 14.22% |
| Income Before Tax | -81.39% | -112.23% | 57.12% | 57.08% | 60.49% |
| Income Tax Expenses | -901.41% | -16.90% | 12.70% | 12.70% | 12.70% |
| Earnings from Continuing Operations | -80.26% | -112.07% | 57.09% | 57.05% | 60.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.26% | -112.07% | 57.09% | 57.05% | 60.46% |
| EBIT | -25.44% | -25.09% | 10.24% | 5.07% | 14.22% |
| EBITDA | -37.63% | -34.87% | 5.89% | 1.15% | 17.58% |
| EPS Basic | -80.62% | -113.47% | 56.05% | 56.02% | 59.56% |
| Normalized Basic EPS | -29.48% | -35.43% | -3.03% | -1.86% | 11.31% |
| EPS Diluted | -80.62% | -113.47% | 56.05% | 56.02% | 59.56% |
| Normalized Diluted EPS | -29.48% | -35.43% | -3.03% | -1.86% | 11.31% |
| Average Basic Shares Outstanding | -0.76% | -1.36% | -1.98% | -2.10% | -1.83% |
| Average Diluted Shares Outstanding | -0.76% | -1.36% | -1.98% | -2.10% | -1.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |